# 1. Financial Performance ## A. Key Figures * **Operating Revenue:** **₹856 Cr** Q4 FY26 (+20.8%) · **₹3,000 Cr+** FY26 Net Income milestone * **Gross Profit:** **₹465 Cr** Q4 FY26 (+21.5%) · **₹1,674 Cr** FY26 (+13.2%) * **Gross Margin:** **54.4%** Q4 FY26 · **56.7%** FY26 * **EBITDA:** **₹195 Cr** Q4 FY26 (+54%) · **₹601 Cr** FY26 * **EBITDA Margin:** **22.8%** Q4 FY26 (+491 bps) · **20.4%** FY26 * **PAT & EPS:** **₹149 Cr** Q4 PAT (+64.3%) · **₹420 Cr** FY26 PAT · **₹9.2** FY26 EPS * **Cash Position:** **₹990 Cr** Cash & Equivalents · **₹328 Cr** Free Cash Flow ## B. Revenue & Profitability Drivers * **Record Earnings Profile:** Achieved highest-ever annual profitability and a major net income milestone, supported by robust global demand and execution. * **Margin Expansion:** Significant year-on-year margin improvement driven by a superior product mix and operational efficiencies, peaking in the final quarter. * **Currency Dynamics:** Company acts as a net beneficiary of currency fluctuations; higher export values for finished goods effectively hedge against rising USD/Yuan-denominated raw material costs. * **Seasonality Trends:** Revenue typically follows a cyclical pattern, troughing in Q1 and peaking in Q3, with Q4 strength contingent on the duration of the winter season. ## C. Balance Sheet & Cash Management * **Capital Strength:** Maintains a debt-free status with a substantial cash reserve, providing significant flexibility for future growth and capital allocation. * **Strategic Inventory Buffering:** Working capital cycle increased to **138 days** due to a deliberate build-up of raw materials and finished goods to mitigate fuel-related price volatility. * **Reinvestment & Capex:** Sustained focus on long-term growth with **INR 131 Cr** deployed toward new facilities and maintenance, alongside an R&D spend representing **3% of revenue**. --- # 2. Geography & Market Mix ## A. Key Figures * **Group Operating Revenue:** **₹2,951 Cr** FY26 (+12.5%) * **North America Revenue:** **₹1,533 Cr** FY26 (+24%) · **₹406 Cr** Q4 (+23.6%) * **UK & EU Revenue:** **₹1,015 Cr** FY26 (34.4% Mix) · **₹308 Cr** Q4 (+12.3%) * **Australia & NZ Revenue:** **₹303 Cr** FY26 (10.3% Mix) · **₹123 Cr** Q4 * **Rest of World Revenue:** **₹99 Cr** FY26 (3.4% Mix) ## B. North America Performance * **Dominant Market Position:** North America remains the primary growth engine, now accounting for over half of total group revenue following robust double-digit annual expansion. * **Sustained Momentum:** Quarterly performance in the U.S. and North America continues to outpace group averages, reinforcing its status as the fastest-growing theater. ## C. UK & Europe Recovery * **Record Quarterly Performance:** The U.K. business saw a significant H2 recovery, culminating in its highest-ever quarterly revenue during Q4. * **European Expansion:** Growth is expected to accelerate via entry into new geographies including **Germany and Ireland**, with financial contributions anticipated in **H2**. ## D. Australia & NZ Expansion * **Strategic Pivot to Rx:** Entry into the Australian prescription segment via **Nova Pharma** with **11 branded generic products** marks a shift beyond traditional OTC capabilities. * **Medium-Term Scaling:** Management has set a roadmap to reach **$100 million** in regional revenue within **3 years**, having already achieved the **50%** milestone. * **Operational Execution:** The region is currently meeting all internal guidance and milestones, supported by strong sequential quarterly growth. ## E. Emerging Market Footprint * **New Market Timelines:** Beyond the European rollout, the company expects to begin seeing revenue contributions from the **Canadian** market toward the **end of the financial year**. --- # 3. Product & Pipeline Progress ## A. Key Figures * **North American Revenue:** **₹1,533 Cr** current (vs. **₹635 Cr** four years prior) * **Product Pipeline:** **112** SKUs launched · **51** additional products in pipeline * **Regulatory Status:** **18** new approvals · **30** under review · **24** awaiting approval * **R&D Intensity:** **3%** of revenue (target for next 3-5 years) ## B. SKU Launches & Market Expansion * **North American Scaling:** Significant multi-year revenue growth supported by aggressive SKU expansion and a consistent quarterly launch cadence. * **Future Launch Targets:** Plans to introduce approximately **50 new products** in the U.S. during **2026-27**, with even larger pipeline expansion anticipated in non-U.S. geographies. ## C. Regulatory Approvals & R&D * **D. K. Market Offensive:** Strategic focus on filing over **200 products** in the U.K. over the next four years to solidify market leadership. * **Niche Differentiation:** Shift toward high-barrier, differentiated products with a typical **one-year** approval cycle; major contributions expected by **late 2027**. * **Canadian Entry:** Filings are currently underway in Canada, with initial approvals slated for the **latter half of the current fiscal year**. ## D. Portfolio Diversification * **Resilience Strategy:** Geographical and portfolio diversification successfully offset early-year pricing pressures in the U.K. market. * **Regional Mix Optimization:** Maintains a balanced portfolio tailored to local dynamics, specifically leveraging a higher tilt toward **Rx products** in the U.K. versus OTC. --- # 4. Manufacturing & Capacity ## A. Key Figures * **Total Operational Capacity:** **2,600 Cr units** total · **1,300–1,400 Cr units** utilized (~50%–55%) * Teva Facility Capacity: 13-14 billion units total · <50% utilized ## B. Facility Utilization & Strategy * **Significant Operating Leverage:** Current utilization levels across all three sites leave substantial headroom for production scaling without immediate large-scale structural builds. * **Asset Clarification:** Management confirmed the company holds **no land bank outside of Goa**, refuting incorrect reports regarding a Nagpur site. ## C. Teva Integration & Capex * **Integration Performance:** The Teva unit acquisition is tracking in line with internal expectations, possessing the potential for **40% to 50%** incremental growth. * **Strategic Capex Allocation:** Future investment within the Teva facility is earmarked for **machinery for new dosage forms** to support the evolving product pipeline. ## D. Infrastructure Expansion * **Long-term Scaling:** To reach the stated billion-dollar revenue capacity, the company is actively evaluating future expansion via **new land banks** or **strategic plant acquisitions**. --- # 5. M&A & Strategic Initiatives ## A. Key Figures * **Net Cash Position:** **₹990 Cr** * **M&A Budget:** **$50M – $60M** * **Dividend:** **₹0.90** per share (90% of face value) * **Regional Ownership:** **60%** stake in Australia/NZ entity ## B. Acquisition Pipeline * **Active Deal Flow:** Management is in advanced discussions with two targets, with **due diligence already underway** for one prospect. * **Geographic Diversification:** Strategy focuses on acquiring platforms and manufacturing assets to expand the European footprint into the **Nordics and Eastern Europe**. * **Disciplined Valuation:** The company maintains a conservative approach to deal-making, prioritizing high ROI and value creation over high-ticket acquisitions. ## C. Strategic Partnerships & Market Entry * **Collaborative Growth:** No immediate plans to buyout the remaining **40% minority stake** in the ANZ business, citing the effectiveness of current partner-led management. * **Organic Expansion:** Planning a direct operational entry into **Canada** to align with upcoming product approvals, marking a key step in global footprint scaling. --- # 6. Supply Chain & Pricing Risks ## A. Key Figures * **Raw Material Cost Inflation:** **20% to 30%** increase * **Inventory Buffer:** **5 to 6 months** of raw materials · Coverage through **Q1** * **Logistics Margin Impact:** ~**2%** drag * **OTC Contract Duration:** **2-year** fixed terms ## B. Raw Material & Inventory Strategy * **Inflationary Headwinds:** Significant cost spikes in petroleum-related ingredients and solvents are expected to pressure margins in **Q1 FY27**. * **Strategic Stockpiling:** High inventory levels serve as a hedge against global trade chaos and potential tariffs, insulating the company from immediate price spikes. * **Profitability Risk:** While current stocks provide a buffer, future margins depend on the duration of geopolitical conflicts; exhausting current inventory would force procurement at elevated market rates. ## C. Logistics & Freight Dynamics * **Manageable Disruptions:** Freight costs are "creeping up" due to the Red Sea crisis, but management views the situation as stable compared to previous peaks. * **Operational Flow:** Despite marginal increases in transit times, container vessels are moving freely; current impacts are largely confined to **fuel surcharges** rather than container scarcity. ## D. Contractual Pricing & Market Exposure * **OTC Pricing Rigidity:** Fixed long-term contracts generally prohibit price adjustments; however, management retains the ability to renegotiate during prolonged crises, as demonstrated during COVID-19. * **Strategic Deferral:** Management is intentionally delaying contract renegotiations, anticipating a sharp market correction and price softening once geopolitical tensions ease. * **Regional Margin Mix:** The U.S. market remains characterized by intense pricing pressure, while the U.K. and Europe currently offer superior margin profiles. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Guidance:** **15% to 20%** Top-line growth (FY27) · **₹4,000 Cr** Target (by FY28) * **EBITDA Margin Guidance:** **20% to 21%** Full-year FY27 * **Current Revenue Base:** **₹3,000 Cr** ## B. Revenue Targets & Growth Roadmap * **Strategic Scaling:** Management aims to double revenue over the next three to five years, viewing current performance as the "tip of the iceberg" relative to existing strategy potential. * **Geographic Drivers:** The U.S. remains the primary growth engine, with increasing strategic weight placed on expansion within the U.K. and European markets. * **Performance Monitoring:** Management advises a year-over-year evaluation of growth objectives rather than quarterly volatility, expressing high optimism for the FY27 trajectory. ## C. Margin Sustainability * **Profitability Resilience:** EBITDA margins are expected to remain stable within the guided range despite headwinds from potential **raw material price inflation**. ## D. Future M&A Timeline * **Capital Allocation:** Significant M&A activity is anticipated in **2027**, focusing on targets that offer geographic entry or complementary strengths. * **Cash Retention:** The company is intentionally retaining its cash corpus to fund these **2027** strategic transactions rather than increasing shareholder distributions.